Scancell Holdings plc (LON:SCLP – Get Free Report) reached a new 52-week high during trading on Friday . The stock traded as high as GBX 14 and last traded at GBX 13.39, with a volume of 1346237 shares traded. The stock had previously closed at GBX 13.50.
Scancell Stock Performance
The business has a 50-day moving average of GBX 12.10 and a 200 day moving average of GBX 10.61. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The company has a market cap of £138.96 million, a PE ratio of -24.35 and a beta of 0.35.
Scancell (LON:SCLP – Get Free Report) last released its quarterly earnings results on Thursday, January 29th. The company reported GBX (0.55) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Featured Stories
- Five stocks we like better than Scancell
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
